anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The identification of Aspergillus species has been performed mainly by morphological classification. In recent years, however, the revelation of the existence of cryptic species has required genetic analysis for accurate identification. The purpose of this study was to investigate five Aspergillus section Nigri strains isolated from a patient and the environment in a university hospital. Species identification by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry identified all five black Aspergillus strains as Aspergillus niger. However, calmodulin gene sequence analysis revealed that all five strains were cryptic species, four of which, including the clinical strain, were Aspergillus tubingensis. Hospital-acquired infection of the patient with the A. tubingensis strain introduced from the environment was suspected, but sequencing of six genes from four A. tubingensis strains revealed no environmental strain that completely matched the patient strain. The amount of in vitro biofilm formation of the four examples of the A. tubingensis strain was comparable to that of Aspergillus fumigatus. An extracellular matrix was observed by electron microscopy of the biofilm of the clinical strain. This study suggests that various types of biofilm-forming A. tubingensis exist in the hospital environment and that appropriate environmental management is required.
1276600 Substituted 3-indenyl acetic acid acid derivatives MERCK & CO Inc 5 Aug 1970 [8 Aug 1969 1 May 1970] 37829/70 Heading C2C Novel compounds of the general Formula I: wherein Ar is aryl or heteroaryl; R 1  is hydrogen, alkyl or haloalkyl; R 2  hydrogen or alkyl; R 3 , R 4 , R 5  and R 6  each are hydrogen, alkyl, acyloxy, alkoxy, nitro, amino, acylamino, alkylamino dialkylamino, dialkylamino alkyl, sulphamoyl, alkylthio, mercapto, hydroxy, hydroxyl alkyl, alkyl sulphonyl, halogen, cyano, carboxyl, alkoxycarbonyl, carbamoyl, haloalkyl cycloalkyl or cycloalkoxyl; R 7  is alkyl sulphinyl or alkyl sulphonyl; R 8  is hydrogen, halogen, hydroxy, alkoxy, alkyl, haloalkyl and M is hydroxy, alkoxy, substituted alkoxy, amino, alkylamino, dialkylamino, N-morpholino, hydroxyalkylamino, polyhydroxyalkylamino, dialkylaminoalkylamino, aminoalkylamino or the group OMe, wherein Me is a cation and the alkyl and alkoxy all being C 1-5  radicals, may be prepared by oxidizing a compound I in which R 7  is alkylthio to sulphoxide and optionally oxidizing the sulphoxide to the sulphone and/or optionally forming metal salts, esters or amides and separating the isomers. The compound I in which R 7  is alkylthio may be prepared by condensing an aldehyde II with an indene III wherein R<SP>*</SP> is an alkyl thio group, and E is an esterifying group; which may in turn be prepared by reacting a halo acetate halo-CH(R 1 )- COOAlk with an indanone IV: to produce III directly or to produce a hydroxyl compound which may be dehydrated to form III. The compound IV may be prepared by cyclizing an acid Va or a reactive derivative thereof): which in turn may be prepared by hydrogenation of the α,#-unsaturated acid VI or by decarboxylation of a malonic acid ester VII: The α,#-unseturated acids VI may be formed by condensation of a substituted benzaldehyde with a substituted haloacetic acid ester, halo- CH(R 2 )COOE or acid anhydride. The malonic ester derivative VII may be prepared by condensing a substituted benzyl halide with a malonic ester R 2 CH(COOE) 2 . The substituted benzaldehyde may be prepared by bromination followed by hydrolysis of the appropriate substituted toluene or Friedel Crafts condensation of Cl 2 CHOCH 3  with the appropriate substituted benzene followed by hydrolysis. Pharmaceutical compositions of the compounds I show anti-inflammatory and analgesic activity when administered topically, orally, rectally or parenterally with the usual excipients.
BACKGROUND: There has been a growing interest in venous thromboembolism following spinal surgery over the past few years. However, there currently needs to be a bibliometric report on this field. This study aims to construct the knowledge structure of venous thromboembolism after spinal surgery and explores the current status of research productivity, research directions, hotspots, and trends.
METHODS: All articles related to venous thromboembolism after spinal surgery from the Web of Science Core Collection database for 1990 to 2023 were retrieved. For bibliometric analysis, information extraction involves country/region, institutions, journals, authors, references, and keyword-related data.
RESULTS: In this study, a total of 814 articles were identified. Studies related to venous thromboembolism after spinal surgery are showing an increasing trend, with the United States contributing the most. JOHNS HOPKINS UNIVERSITY is a high-productivity institution. The journal "SPINE" is highly productive. Research directions cover venous thromboembolism and bleeding, risk factors and prevention, complications, and perioperative blood protection strategies. Current research hotspots are risk factors, surgical location and approach, and perioperative blood protection strategies. Future research trends include establishing a predictive system for venous thromboembolism after spinal surgery to guide personalized prevention and treatment.
CONCLUSIONS: This study constructed the knowledge structure of venous thromboembolism after spinal surgery, revealing current research hotspots and future trends. Future research trends include personalized prevention and treatment strategies for venous thromboembolism after spinal surgery, especially safe and effective chemical prophylaxis. It is hoped that this study can lay the foundation for subsequent research.
Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
Utilizing graphical elements representing human bodies to estimate physical measurements of a user is described. In at least one example, a service provider can access a database storing a plurality of data items. The service provider can cause a set of data items of the plurality of data items to be presented to the user. Data items in the set of data items are associated with at least one graphical element representing a human body with individual magnitudes corresponding to individual dimensions of a plurality of dimensions. The service provider can receive data indicating a selection of a data item associated with a first magnitude associated with a first dimension and a second magnitude associated with a second dimension. The service provider can estimate physical measurements associated with the user based partly on a first magnitude and/or the second magnitude.
Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
The incidence of colorectal cancer ranks fourth worldwide after lung, prostate and breast cancers. Although chemotherapy has an important place in the treatment of colorectal cancers, it can cause side effects such as diarrhea and fatigue in patients. Cancer patients' ability to cope with treatment side effects can be benefited from technological developments. Studies have shown that mobile health applications reduce symptom experience and increase quality of life in patients with breast cancer and leukemia. This research was planned as a quasi-experimental study with a pre-test-post-test control group in order to examine the effects of the mobile health application developed according to the Self-Care Disability Theory and the training given for chemotherapy side effects on the quality of life of colorectal cancer patients. The sample of the study will consist of patients who underwent chemotherapy outpatient (23 intervention group and 23 control group) with the diagnosis of colorectal cancer in the Internal Medicine Medical Oncology outpatient clinic of Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty. Simple random sampling method, which is one of the probabilistic sampling methods, will be used to determine the intervention and control groups. Data will be obtained (pre-test) with the Patient Information Form, the Self-Care Needs Assessment Form, the Nightingale Symptom Assessment Scale (N-SDS), and the Cancer Treatment Functional Assessment-Colorectal Scale (FACT-C). Training will be provided to the initiative group through the mobile health application. Symptom management and quality of life will be evaluated by using data collection tools after the 1st and 2nd cycles of chemotherapy in intervention group patients. A face-to-face meeting with the initiative group is planned every two weeks. Once a week, an message will be sent to the intervention group patients reminding them to use the mobile health application. Control group patients will continue to receive routine treatment and follow-up. A post-test will be applied to the intervention and control groups in the third month (12 weeks after the first interview). In this study, it is aimed to compare the effectiveness of routine treatment and care with the use of a mobile health application developed according to the Self-Care Insufficiency Theory, considering the developments in today's technology, and to evaluate the effects of the two methods on the control of symptoms that may occur due to chemotherapy side effects in colorectal cancer patients and their care needs.
Safety and effectiveness in pediatric patients have not been established. Sumatriptan tablets are not recommended for use in patients younger than 18 years of age.   
  
Two controlled clinical trials evaluated sumatriptan nasal spray (5 to 20 mg) in 1,248 adolescent migraineurs aged 12 to 17 years who treated a single attack. The trials did not establish the efficacy of sumatriptan nasal spray compared with placebo in the treatment of migraine in adolescents. Adverse reactions observed in these clinical trials were similar in nature to those reported in clinical trials in adults.   
  
Five controlled clinical trials (2 single-attack trials, 3 multiple-attack trials) evaluating oral sumatriptan (25 to 100 mg) in pediatric patients aged 12 to 17 years enrolled a total of 701 adolescent migraineurs. These trials did not establish the efficacy of oral sumatriptan compared with placebo in the treatment of migraine in adolescents. Adverse reactions observed in these clinical trials were similar in nature to those reported in clinical trials in adults. The frequency of all adverse reactions in these patients appeared to be both dose - and age-dependent, with younger patients reporting reactions more commonly than older adolescents.   
  
Postmarketing experience documents that serious adverse reactions have occurred in the pediatric population after use of subcutaneous, oral, and/or intranasal sumatriptan. These reports include reactions similar in nature to those reported rarely in adults, including stroke, visual loss, and death. A myocardial infarction has been reported in a 14-year-old male following the use of oral sumatriptan; clinical signs occurred within 1 day of drug administration. Clinical data to determine the frequency of serious adverse reactions in pediatric patients who might receive subcutaneous, oral, or intranasal sumatriptan are not presently available.
Liquid pharmaceutical composition for the oral administration of active substances that are bitter and susceptible to hydrolysis. The composition (for 100 ml) comprises: 3-15 g of active substance 0.01-0.3 g of preservative (sorbic acid, methyl p-hydroxybenzoate) sufficient amount of an edible oily vehicle formed by triglycerides of short- or medium-chain acids (caprylic, capric) to make up 100 ml a suitable quantity of sweetener (sodium saccharin, sodium cyclamate, ammonium glycyrricinate) optionally accompanied by a suitable amount of a flavouring agent (walnut, condensed milk, coconut, banana) 0.5-2 g of soya lecithin 0.1-5 g of thickener of the type derived from cellulose (N-ethylcellulose) and 0.05-1 g of a polysorbate type surfactant. Optionally it includes 0.5-5 g of mannitol and 1-5 g of sodium bicarbonate. It is useful for the administration of bitter active substances (ciprofloxacin, paracetamol, erythromycin etc.) in children, the elderly and patients who are little motivated. It is stable, easy to ingest and of bearable taste.
Patients should be informed of the potential risks and advantages of Humalog Mix75/25 and alternative therapies. Patients should not mix Humalog Mix75/25 with any other insulin. They should also be informed about the importance of proper insulin storage, injection technique, timing of dosage, adherence to meal planning, regular physical activity, regular blood glucose monitoring, periodic hemoglobin A1c testing, recognition and management of hypo- and hyperglycemia, and periodic assessment for diabetes complications.

Patients should be advised to inform their physician if they are pregnant or intend to become pregnant.

Refer patients to the Patient Information leaflet for information on normal appearance, timing of dosing (within 15 minutes before a meal), storing, and common adverse effects.

For Patients Using Insulin Pen Delivery Devices: Before starting therapy, patients should read the Patient Information leaflet that accompanies the drug product and the User Manual that accompanies the delivery device and re-read them each time the prescription is renewed. Patients should be instructed on how to properly use the delivery device, prime the Pen to a stream of insulin, and properly dispose of needles. Patients should be advised not to share their Pens with others.
Prepubertal obesity is growing at an alarming rate and is now considered a risk factor for renal injury. Recently, we reported that the early development of renal injury in obese Dahl salt-sensitive (SS) leptin receptor mutant (SS LepR mutant) rats was associated with increased T-cell infiltration and activation before puberty. Therefore, the current study investigated the effect of inhibiting T-cell activation with abatacept on the progression of renal injury in young obese SS LepR mutant rats before puberty. Four-week-old SS and SS LepR mutant rats were treated with IgG or abatacept (1 mg/kg; ip, every other day) for 4 weeks. Abatacept reduced the renal infiltration of T cells by almost 50% in SS LepR mutant rats. Treatment with abatacept decreased the renal expression of macrophage inflammatory protein-3 alpha while increasing IL-4 in SS LepR mutant rats without affecting SS rats. While not having an impact on blood glucose levels, abatacept reduced hyperinsulinemia and plasma triglycerides in SS LepR mutant rats without affecting SS rats. We did not observe any differences in the mean arterial pressure among the groups. Proteinuria was markedly higher in SS LepR mutant rats than in SS rats throughout the study, and treatment with abatacept decreased proteinuria by about 40% in SS LepR mutant rats without affecting SS rats. We observed significant increases in glomerular and tubular injury and renal fibrosis in SS LepR mutant rats versus SS rats, and chronic treatment with abatacept significantly reduced these renal abnormalities in SS LepR mutant rats. These data suggest that renal T-cell activation contributes to the early progression of renal injury associated with prepubertal obesity.
Disclosed herein are embodiments of systems, methods, and products comprises an analytic server, which determines user health attributes by tracking the user’s behaviors and activities within a predetermined space. The analytic server receives tracking data from a set of sensors installed in the predetermined space. The sensors track a beacon worn by the user. The analytic server determines micro-locations and user behaviors based on the tracking data. The analytic server determines the coordinates of the sensors based on the sensor identifiers and maps the coordinates to regions by referring to a floor plan map. The analytic server determines the user behaviors and activities by aggregating the micro-locations and regions the user visited at different time. The analytic server determines the user’s health score based on the micro-locations and user behaviors by executing an artificial intelligence model. The analytic server determines a recommendation of premium based on the health score.
Infection before primary vaccination (herein termed "hybrid immunity") engenders robust humoral immunity and broad Ab-dependent cell-mediated cytotoxicity (ADCC) across SARS-CoV-2 variants. We measured and compared plasma IgG and IgA against Wuhan-Hu-1 and Omicron (B.1.1.529) full-length spike (FLS) and receptor binding domain after three mRNA vaccines encoding Wuhan-Hu-1 spike (S) and after Omicron breakthrough infection. We also measured IgG binding to Wuhan-Hu-1 and Omicron S1, Wuhan-Hu-1 S2 and Wuhan-Hu-1 and Omicron cell-based S. We compared ADCC using human embryonic lung fibroblast (MRC-5) cells expressing Wuhan-Hu-1 or Omicron S. The effect of Omicron breakthrough infection on IgG anti-Wuhan-Hu-1 and Omicron FLS avidity was also considered. Despite Omicron breakthrough infection increasing IgG and IgA against FLS and receptor binding domain to levels similar to those seen with hybrid immunity, there was no boost to ADCC. Preferential recognition of Wuhan-Hu-1 persisted following Omicron breakthrough infection, which increased IgG avidity against Wuhan-Hu-1 FLS. Despite similar total anti-FLS IgG levels following breakthrough infection, 4-fold higher plasma concentrations were required to elicit ADCC comparable to that elicited by hybrid immunity. The greater capacity for hybrid immunity to elicit ADCC was associated with a differential IgG reactivity pattern against S1, S2, and linear determinants throughout FLS. Immunity against SARS-CoV-2 following Omicron breakthrough infection manifests significantly less ADCC capacity than hybrid immunity. Thus, the sequence of antigenic exposure by infection versus vaccination and other factors such as severity of infection affect antiviral functions of humoral immunity in the absence of overt quantitative differences in the humoral response.
Risk Summary

Methotrexate Injection is contraindicated in pregnant women with non-neoplastic diseases. Based on published reports and its mechanism of action, methotrexate can cause embryo-fetal toxicity and fetal death when administered to a pregnant woman [see Data and Clinical Pharmacology (12.1)]. There are no animal data that meet current standards for nonclinical developmental toxicity studies. Advise pregnant women with neoplastic diseases of the potential risk to a fetus. The preservative benzyl alcohol can cross the placenta; when possible, use the preservative-free formulation when Methotrexate Injection is needed during pregnancy to treat a neoplastic disease [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4)].

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

Data

Human Data

Published data from case reports, literature reviews, and observational studies report that methotrexate exposure during pregnancy is associated with an increased risk of embryo-fetal toxicity and fetal death. Methotrexate exposure during the first trimester of pregnancy is associated with an increased incidence of spontaneous abortions and multiple adverse developmental outcomes, including skull anomalies, facial dysmorphism, CNS abnormalities, limb abnormalities, and sometimes cardiac anomalies and intellectual impairment. Adverse outcomes associated with exposure during second and third trimesters of pregnancy include intrauterine growth restriction and functional abnormalities. Because methotrexate is widely distributed and persists in the body for a prolonged period, there is a potential risk to the fetus from preconception methotrexate exposure.

A prospective multicenter study evaluated pregnancy outcomes in women taking methotrexate less than or equal to 30 mg/week after conception. The rate of spontaneous abortion/miscarriage in pregnant women exposed to methotrexate was 42.5% (95% confidence interval [95% CI] 29.2–58.7), which was higher than in unexposed patients with autoimmune disease (22.5%, 95% CI 16.8–29.7) and unexposed patients with non-autoimmune disease (17.3%, 95% CI 13–22.8). Of the live births, the rate of major birth defects in pregnant women exposed to methotrexate after conception was higher than in unexposed patients with autoimmune disease (adjusted odds ratio (OR) 1.8 [95% CI 0.6–5.7]) and unexposed patients with non-autoimmune disease (adjusted OR 3.1 [95% CI 1.03–9.5]) (2.9%). Major birth defects associated with pregnancies exposed to methotrexate after conception were not always consistent with methotrexate-associated adverse developmental outcomes.
Recombinant sarbecovirus vaccine based on the nucleocapsid of SARS-CoV-2. One single administration intramuscularly of a 500µg (1.0mL) dose on Day 1.
The present invention relates to a traditional Chinese medicine gel for treating cervicitis and cervical erosion and a preparing method thereof. The gel is composed of components of the following percentage by weight: 5 to 50% flavescent sophora roots total extracts, 3 to 25 % Nauclea gambir total extracts, 20 to 60 % acid solvent, 10 to 50 % polar solvent and 0.5 to 10% macromolecule adhere materials. The gel used as a preparation for vaginas of women is firstly put forward by the present invention and can be directly used for a position catching a disease. The present invention has the advantages of strong pertinence, small interference for the internal environment of an organism and quick doing execution, and thus, the present invention can well exert therapeutic effect. The present invention also provides a preparing method for the gel and solves the imcompatible problem that tannin in Nauclea gambir is matched with alkaloid in flavescent sophora root. The made gel can be completely gel, cream bodies are exquisite and lucidus.